Four types of cannabimimetic indazole and indole derivatives, ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA, identified as new psychoactive substances

Forensic Toxicology

Volumn 34, Issue 1, 2016, Pages 133-143

  Qian, Zhenhua ^a   Hua, Zhendong ^a   Liu, Cuimei ^a   Jia, Wei ^a  

^a Drug Intelligence and Forensic Center of Minister of Public Security   (China)

Author keywords

N (1 Amino 3,3 dimethyl 1 oxobutan 2 yl) 1 (4 fluorobenzyl) 1H indole 3 carboxamide (ADB FUBICA); N (1 Amino 3,3 dimethyl 1 oxobutan 2 yl) 1 benzyl 1H indazole 3 carboxamide (ADB BINACA); N (1 Amino 3 methyl 1 oxobutan 2 yl) 1 (4 fluorobenzyl) 1H indole 3 carboxamide (AB FUBICA); N (1 Amino 3 methyl 1 oxobutan 2 yl) 1 benzyl 1H indole 3 carboxamide (AB BICA); New psychoactive substance; Synthetic cannabinoid

Indexed keywords

CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ILLICIT DRUG; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; N (1 AMINO 3 METHYL 1 OXOBUTAN 2 YL) 1 (4 FLUOROBENZYL) 1H INDAZOLE 3 CARBOXAMIDE; N (1 AMINO 3 METHYL 1 OXOBUTAN 2 YL) 1 (4 FLUOROBENZYL) 1H INDOLE 3 CARBOXAMIDE; N (1 AMINO 3 METHYL 1 OXOBUTAN 2 YL) 1 BENZYL 1H INDOLE 3 CARBOXAMIDE; N (1 AMINO 3,3 DIMETHYL 1 OXOBUTAN 2 YL) 1 (4 FLUOROBENZYL) 1H INDOLE 3 CARBOXAMIDE; N (1 AMINO 3,3 DIMETHYL 1 OXOBUTAN 2 YL) 1 BENZYL 1H INDAZOLE 3 CARBOXAMIDE; PSYCHOTROPIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL STRUCTURE; CHINA; FORENSIC TOXICOLOGY; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ANALYSIS;

EID: 84953347538     PISSN: 18608965     EISSN: 18608973     Source Type: Journal    
DOI: 10.1007/s11419-015-0297-2     Document Type: Article

References (11)

1. EMCDDA (2015) New psychoactive substances in Europe: an update from the EU Early Warning System. European Monitoring Centre for Drugs and Drug Addiction. http://www.emcdda.europa.eu/publications/2015/new-psychoactive-substances. Accessed May 2015
2. EMCDDA (2014) European drug report 2014: trends and developments. http://www.emcdda.europa.eu/attachements.cfm/att_228272_EN_TDAT14001ENN.pdf. Accessed Nov 2014
3. SMART (2015) Global smart update: legal responses to NPS: multiple approaches to a multi-faceted problem. http://www.unodc.org/documents/scientific/Global_SMART_Update_14-web.pdf. Accessed Sep 2015
4. Kikura-Hanajiri R, Uchiyama N, Kawamura M, Goda Y (2014) Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan. Drug Test Anal 6:832–839
5. Zuba D, Byrska B (2013) Analysis of the prevalence and coexistence of synthetic cannabinoids in “herbal high” products in Poland. Forensic Toxicol 31:21–30
6. Chung H, Choi H, Heo S, Kim E, Lee J (2014) Synthetic cannabinoids abused in South Korea: drug identifications by the National Forensic Service from 2009 to June 2013. Forensic Toxicol 32:82–88
7. Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Glass M, Connor M, McGregor IS, Kassiou M (2015) Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA,5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chem Neurosci. 6:1546–1559
8. Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2013) Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products. Forensic Toxicol 31:223–240
9. Uchiyama N, Matsuda S, Wakana D, Kikura-Hanajiri R, Goda Y (2013) New cannabimimetic indazole derivatives, N-(1-amino-3- methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA), identified as designer drugs in illegal products. Forensic Toxicol 31:93–100
10. 1-mediated diseases. Patent: WO/2009/106982 September, 2009
11. http://www.caymanchem.com/app/template/SpectralLibrary.vm. Accessed 24 April 2014